Assets
83 molecules in the GLP-1 and incretin landscape.
Each molecule shows its trial count, geographic footprint, and the mix of outcomes it is measured against. Open any molecule for the full breakdown.
83 molecules. Source: ClinicalTrials.gov, as of July 1, 2026.
83 of 83
Oral / Subcutaneous · GLP-1 agonist
Semaglutide
12,389 endpoints measured
706
Trials
331
Active47%
7,071
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 agonist
Liraglutide
8,082 endpoints measured
514
Trials
44
Active9%
3,598
Sites
Endpoint mix
scaled within asset
Intravenous / Subcutaneous · GLP-1 agonist
Exenatide
3,029 endpoints measured
384
Trials
19
Active5%
3,304
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / GIP dual
Tirzepatide
3,486 endpoints measured
249
Trials
164
Active66%
3,030
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 agonist
Dulaglutide
2,224 endpoints measured
136
Trials
25
Active18%
2,352
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 agonist
Lixisenatide
906 endpoints measured
79
Trials
9
Active11%
2,091
Sites
Endpoint mix
scaled within asset
Intravenous / Subcutaneous · Amylin analog
Pramlintide
484 endpoints measured
63
Trials
4
Active6%
270
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / amylin
CagriSema / cagrilintide
1,049 endpoints measured
52
Trials
22
Active42%
1,915
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 agonist
Orforglipron
462 endpoints measured
47
Trials
15
Active32%
1,640
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 agonist
Albiglutide
530 endpoints measured
39
Trials
3
Active8%
1,375
Sites
Endpoint mix
scaled within asset
Oral / Subcutaneous · GLP-1 / GIP dual
HRS9531
464 endpoints measured
37
Trials
20
Active54%
152
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / glucagon dual
Mazdutide
477 endpoints measured
35
Trials
19
Active54%
144
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / GIP / glucagon triple
Retatrutide
308 endpoints measured
34
Trials
15
Active44%
1,572
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / glucagon dual
Survodutide
330 endpoints measured
31
Trials
9
Active29%
1,310
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 agonist
GZR18
217 endpoints measured
26
Trials
18
Active69%
38
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / glucagon dual
Cotadutide
450 endpoints measured
24
Trials
0
Active0%
341
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 agonist / GIP antagonist
Maridebart cafraglutide / MariTide
410 endpoints measured
24
Trials
15
Active63%
1,462
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 agonist
KAI-7535 / HRS-7535
185 endpoints measured
22
Trials
7
Active32%
36
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 / amylin
Amycretin / zenagamtide
368 endpoints measured
21
Trials
12
Active57%
1,279
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 agonist
Danuglipron
402 endpoints measured
20
Trials
0
Active0%
153
Sites
Endpoint mix
scaled within asset
Subcutaneous · Amylin analog
Eloralintide
153 endpoints measured
17
Trials
11
Active65%
678
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 agonist
AZD5004 / ECC5004
256 endpoints measured
16
Trials
2
Active13%
155
Sites
Endpoint mix
scaled within asset
Oral / Subcutaneous · GLP-1 / GIP dual
BGM0504
91 endpoints measured
15
Trials
10
Active67%
10
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / glucagon dual
Efinopegdutide
244 endpoints measured
15
Trials
1
Active7%
336
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / glucagon dual
Pemvidutide
89 endpoints measured
15
Trials
2
Active13%
158
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 agonist
Efpeglenatide
94 endpoints measured
14
Trials
2
Active14%
461
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 agonist
Loxenatide / PEG-loxenatide
60 endpoints measured
14
Trials
2
Active14%
10
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 agonist
HDM1002
144 endpoints measured
13
Trials
11
Active85%
37
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 agonist
Taspoglutide
50 endpoints measured
13
Trials
0
Active0%
840
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 agonist
MET097 / PF-08653944
203 endpoints measured
12
Trials
9
Active75%
243
Sites
Endpoint mix
scaled within asset
Subcutaneous · Amylin analog
AZD6234
207 endpoints measured
11
Trials
7
Active64%
123
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 agonist
Lotiglipron
392 endpoints measured
11
Trials
0
Active0%
91
Sites
Endpoint mix
scaled within asset
Subcutaneous · FGF21 analog
NNC0194-0499
118 endpoints measured
11
Trials
1
Active9%
308
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / GIP dual
NNC0519-0130
91 endpoints measured
11
Trials
1
Active9%
274
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / GIP dual
RAY1225
45 endpoints measured
11
Trials
8
Active73%
6
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 agonist
TG103
145 endpoints measured
11
Trials
0
Active0%
6
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 agonist
Ecnoglutide (XW003)
98 endpoints measured
10
Trials
3
Active30%
8
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / GIP dual
HDM1005
75 endpoints measured
10
Trials
8
Active80%
6
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 agonist
Aleniglipron / GSBR-1290
121 endpoints measured
9
Trials
5
Active56%
207
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 agonist
Noiiglutide / HS-20004 / SHR20004
91 endpoints measured
9
Trials
1
Active11%
7
Sites
Endpoint mix
scaled within asset
Subcutaneous · Amylin analog
Petrelintide
123 endpoints measured
8
Trials
3
Active38%
76
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / GIP / glucagon triple
UBT251
100 endpoints measured
8
Trials
6
Active75%
9
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 agonist
Beinaglutide
97 endpoints measured
7
Trials
2
Active29%
26
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / GIP dual
CT-388
169 endpoints measured
7
Trials
5
Active71%
187
Sites
Endpoint mix
scaled within asset
Subcutaneous · GIP agonist
Macupatide
37 endpoints measured
7
Trials
3
Active43%
93
Sites
Endpoint mix
scaled within asset
Subcutaneous · GIP agonist
NNC0480-0389
62 endpoints measured
7
Trials
0
Active0%
132
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / glucagon dual
AZD9550
147 endpoints measured
6
Trials
5
Active83%
72
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 agonist
CT-996 / RO7795081
76 endpoints measured
6
Trials
4
Active67%
72
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 agonist
MDR-001
78 endpoints measured
6
Trials
6
Active100%
57
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / glucagon dual
SAR425899
97 endpoints measured
6
Trials
0
Active0%
62
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / GLP-2 dual
Dapiglutide
115 endpoints measured
5
Trials
1
Active20%
2
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / GIP dual
VK2735
12 endpoints measured
5
Trials
2
Active40%
148
Sites
Endpoint mix
scaled within asset
Subcutaneous · Amylin analog
ABBV-295
27 endpoints measured
4
Trials
3
Active75%
3
Sites
Endpoint mix
scaled within asset
Oral / Subcutaneous · GLP-1 agonist
ASC30
16 endpoints measured
4
Trials
2
Active50%
13
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / GIP dual
CT-868
45 endpoints measured
4
Trials
0
Active0%
28
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / glucagon / FGF21 triple
DR10624
80 endpoints measured
4
Trials
2
Active50%
39
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / FGF21 dual
HEC88473
34 endpoints measured
4
Trials
1
Active25%
5
Sites
Endpoint mix
scaled within asset
Oral / Subcutaneous · GLP-1 / GLP-2 dual
PG-102 / RT-114
43 endpoints measured
4
Trials
3
Active75%
16
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / GIP / glucagon triple
Efocipegtrutide
7 endpoints measured
3
Trials
1
Active33%
62
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 / GIP / glucagon triple
NA-931
25 endpoints measured
3
Trials
1
Active33%
23
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 agonist
RGT001-075 / RGT-075
58 endpoints measured
3
Trials
0
Active0%
37
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / glucagon dual
DD01
45 endpoints measured
2
Trials
0
Active0%
16
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 agonist
Ecnoglutide (VRB-101)
13 endpoints measured
2
Trials
2
Active100%
36
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 agonist
Ecnoglutide (XW004)
13 endpoints measured
2
Trials
1
Active50%
2
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 agonist
GL0034 / utreglutide
10 endpoints measured
2
Trials
2
Active100%
24
Sites
Endpoint mix
scaled within asset
Subcutaneous · Amylin analog
MET233
25 endpoints measured
2
Trials
1
Active50%
1
Sites
Endpoint mix
scaled within asset
Inhaled · GLP-1 agonist
MKC253
4 endpoints measured
2
Trials
0
Active0%
1
Sites
Endpoint mix
scaled within asset
Subcutaneous · PYY / Y2 agonist
NNC0165-1875
35 endpoints measured
2
Trials
0
Active0%
26
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / glucagon dual
PB-718
14 endpoints measured
2
Trials
0
Active0%
2
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 agonist
PF-04603629
8 endpoints measured
2
Trials
0
Active0%
5
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 agonist
ZT006
31 endpoints measured
2
Trials
1
Active50%
11
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / glucagon dual
DA-1726
4 endpoints measured
1
Trials
1
Active100%
1
Sites
Endpoint mix
scaled within asset
Oral / Subcutaneous · GLP-1 agonist
Ecnoglutide
11 endpoints measured
1
Trials
1
Active100%
0
Sites
Endpoint mix
scaled within asset
Subcutaneous · Amylin analog
KBP-042
6 endpoints measured
1
Trials
0
Active0%
29
Sites
Endpoint mix
scaled within asset
Subcutaneous · Amylin analog
KBP-089
24 endpoints measured
1
Trials
0
Active0%
1
Sites
Endpoint mix
scaled within asset
Subcutaneous · Amylin analog
KBP-336
15 endpoints measured
1
Trials
1
Active100%
20
Sites
Endpoint mix
scaled within asset
Subcutaneous · Amylin analog
NNC0638-0355
6 endpoints measured
1
Trials
1
Active100%
1
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / glucagon dual
OPK88003
4 endpoints measured
1
Trials
0
Active0%
3
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / GIP dual
RG7697 / MAR709
10 endpoints measured
1
Trials
0
Active0%
20
Sites
Endpoint mix
scaled within asset
Subcutaneous · GLP-1 / GIP / glucagon triple
SAR441255
7 endpoints measured
1
Trials
0
Active0%
1
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 agonist
TERN-601
3 endpoints measured
1
Trials
0
Active0%
17
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 agonist
TTP273
16 endpoints measured
1
Trials
0
Active0%
29
Sites
Endpoint mix
scaled within asset
Oral · GLP-1 agonist
XW014
2 endpoints measured
1
Trials
0
Active0%
3
Sites
Endpoint mix
scaled within asset